231 related articles for article (PubMed ID: 26686269)
1. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
Cerini F; Vilaseca M; Lafoz E; García-Irigoyen O; García-Calderó H; Tripathi DM; Avila M; Reverter JC; Bosch J; Gracia-Sancho J; García-Pagán JC
J Hepatol; 2016 Apr; 64(4):834-42. PubMed ID: 26686269
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
3. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
[TBL] [Abstract][Full Text] [Related]
4. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
5. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
6. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
7. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis.
Delgado MG; Gracia-Sancho J; Marrone G; Rodríguez-Vilarrupla A; Deulofeu R; Abraldes JG; Bosch J; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2013 Oct; 305(7):G496-502. PubMed ID: 23886859
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
9. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
Tripathi DM; Erice E; Lafoz E; García-Calderó H; Sarin SK; Bosch J; Gracia-Sancho J; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G301-9. PubMed ID: 26138461
[TBL] [Abstract][Full Text] [Related]
10. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
[TBL] [Abstract][Full Text] [Related]
11. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
Klein S; Van Beuge MM; Granzow M; Beljaars L; Schierwagen R; Kilic S; Heidari I; Huss S; Sauerbruch T; Poelstra K; Trebicka J
J Hepatol; 2012 Dec; 57(6):1220-7. PubMed ID: 22878469
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.
Fortea JI; Zipprich A; Fernandez-Mena C; Puerto M; Bosoi CR; Almagro J; Hollenbach M; Bañares J; Rodríguez-Sánchez B; Cercenado E; Clément MA; Rose CF; Bañares R; Vaquero J; Ripoll C
Liver Int; 2018 Jan; 38(1):102-112. PubMed ID: 28665498
[TBL] [Abstract][Full Text] [Related]
13. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance.
Kojima H; Yamao J; Tsujimoto T; Uemura M; Takaya A; Fukui H
J Hepatol; 2000 Jan; 32(1):43-50. PubMed ID: 10673066
[TBL] [Abstract][Full Text] [Related]
14. Improvement of portal hypertension and hepatic blood flow in cirrhotic rats by oestrogen.
Sakamoto M; Ueno T; Nakamura T; Sakata R; Hasimoto O; Torimura T; Sata M
Eur J Clin Invest; 2005 Mar; 35(3):220-5. PubMed ID: 15733078
[TBL] [Abstract][Full Text] [Related]
15. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
16. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability.
Lee KC; Yang YY; Huang YT; Lee FY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2010 Apr; 119(1):45-55. PubMed ID: 20132096
[TBL] [Abstract][Full Text] [Related]
17. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
[TBL] [Abstract][Full Text] [Related]
18. The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats.
Rodríguez S; Raurell I; Ezkurdia N; Augustin S; Esteban R; Genescà J; Martell M
Liver Int; 2015 Feb; 35(2):326-34. PubMed ID: 24517276
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren reduces portal pressure and intrahepatic resistance in biliary cirrhotic rats.
Hsieh YC; Chan CC; Lee KC; Huang YT; Lee FY; Yang YY; Lin HC
J Chin Med Assoc; 2012 Oct; 75(10):501-8. PubMed ID: 23089401
[TBL] [Abstract][Full Text] [Related]
20. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats.
Thabut D; Tazi KA; Bonnefont-Rousselot D; Aller M; Farges O; Guimont MC; Tellier Z; Guichard C; Ogier-Denis E; Poynard T; Moreau R; Lebrec D
Hepatology; 2007 Dec; 46(6):1893-906. PubMed ID: 17918268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
